Cyclic and linear peptides derived from alpha-amylase inhibitory protein tendamistat. 2001

S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
Department of System Engineering of Materials and Life Science, Faculty of Engineering, Toyama University, Gofuku, Toyama 930-8555, Japan. shinono@eng.toyama-u.ac.jp

Tendamistat is a strong inhibitory protein of porcine pancreatic alpha-amylase (PPA) with a K(i) value of 0.2 nM. To develop potent alpha-amylase inhibitors, we synthesized six odd-length cyclic peptides (5-15 residues) and four even-length cyclic peptides (10 and 12 residues) having the inhibitory sequence of tendamistat. Their PPA inhibitory activities were evaluated, and, among them, the 11-residue cyclic peptide Ten(15-23) (K(i) = 0.27 microM) exhibited the strongest inhibitory activity (K(i) = 0.27-1.41 microM). To examine the effect of cyclic structure on PPA inhibition, ten linear peptides corresponding to the cyclic peptides were also synthesized, and their PPA inhibitory activities were evaluated (K(i) = 0.28-1.00 microM). Interestingly, the 11-residue linear peptide Ten(15-23) exhibited almost the same inhibitory activity (K(i) = 0.28 microM) as that of cyclic Ten(15-23). The results of a circular dichroism study indicated that stabilization of the beta-hairpin structure occurred only for cyclic Ten(15-23). Also, the results of proteolytic digestion experiments of the cyclic and linear Ten(15-23) peptides by trypsin and chymotrypsin suggested no differences in protease resistance between the cyclic and linear structures. Therefore, we demonstrated that both cyclic and linear peptides containing the inhibitory sequence of tendamistat exhibit potent PPA inhibitory activity.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D002918 Chymotrypsin A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side. Alpha-Chymotrypsin Choay,Alphacutanée,Avazyme
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000516 alpha-Amylases Enzymes that catalyze the endohydrolysis of 1,4-alpha-glycosidic linkages in STARCH; GLYCOGEN; and related POLYSACCHARIDES and OLIGOSACCHARIDES containing 3 or more 1,4-alpha-linked D-glucose units. Taka-Amylase A,alpha-Amylase,Alpha-Amylase Bayer,Maxilase,Mégamylase,alpha-1,4-D-Glucanglucanohydrolase,Alpha Amylase Bayer,AlphaAmylase Bayer,Taka Amylase A,TakaAmylase A,alpha 1,4 D Glucanglucanohydrolase,alpha Amylase,alpha Amylases
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
August 1998, Bioscience, biotechnology, and biochemistry,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
July 2005, Bioorganic & medicinal chemistry,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
November 2002, Journal of immunological methods,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
May 2013, Current protein & peptide science,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
October 2003, Acta crystallographica. Section D, Biological crystallography,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
March 1994, European journal of biochemistry,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
June 1984, European journal of biochemistry,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
June 1999, Die Nahrung,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
March 2021, Journal of the science of food and agriculture,
S Ono, and M Umezaki, and N Tojo, and S Hashimoto, and H Taniyama, and T Kaneko, and T Fujii, and H Morita, and C Shimasaki, and I Yamazaki, and T Yoshimura, and T Kato
June 2008, Journal of natural products,
Copied contents to your clipboard!